Get the Stockscreener App
152.74
0.50%
-0.7472
Illumina Inc stock is traded at $152.74, with a volume of 1.70M.
It is down -0.50% in the last 24 hours and up +7.99% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$153.49
Open:
$148.13
24h Volume:
1.70M
Relative Volume:
1.00
Market Cap:
$24.23B
Revenue:
$4.43B
Net Income/Loss:
$-3.04B
P/E Ratio:
-5.7401
EPS:
-26.61
Net Cash Flow:
$357.00M
1W Performance:
+4.61%
1M Performance:
+7.99%
6M Performance:
+29.50%
1Y Performance:
+30.62%
1-Day Range:
$147.10
$155.15
1-Week Range:
$142.91
$155.37
52-Week Range:
$89.00
$155.37
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina: Q3 Confirms Improving Fundamentals (ILMN) - Seeking Alpha
Illumina's SWOT analysis: stock outlook amid sequencing market shifts - Investing.com
Illumina's SWOT analysis: stock outlook amid sequencing market shifts By Investing.com - Investing.com UK
Illumina shares target raised, buy rating continued on strong Q3 - Investing.com
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket - Yahoo Finance
Illumina (NASDAQ:ILMN) Posts Earnings Results - MarketBeat
Illumina maintains stock target, rating held on growth potential - Investing.com
Illumina, Inc. (NASDAQ:ILMN) Q3 2024 Earnings Call Transcript - Insider Monkey
Illumina stock target lifted amid strong margins and consumables drive growth - Investing.com
Illumina revenue dips 2% to USD 1.1 billion for Q3 2024 - Medical Buyer
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Van ECK Associates Corp - MarketBeat
Bioinformatics Market Forecasted to Reach $29.1 Billion by 2031 | Illumina Inc., Thermo Fischer Scientific, Qiagen NV - openPR
Earnings call: Illumina reports mixed Q3 results, plans for future growth - Investing.com
Vanguard Group Inc's Strategic Acquisition of Illumina Inc Shares - GuruFocus.com
Illumina Introduces the MiSeq i100 Series - MPO-mag
Illumina Reports Q3 2024 Financial Results Amid Strategic Expansion - TipRanks
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - TradingView
Illumina: Q3 Earnings Snapshot - San Antonio Express-News
Illumina (NASDAQ:ILMN) Updates FY 2024 Earnings Guidance - MarketBeat
Illumina stock falls 6% amid lowered 2024 revenue guidance - MSN
Illumina stock falls 6% amid lowered 2024 revenue guidance (NASDAQ:ILMN) - Seeking Alpha
Illumina shares fall 5% as Q4 revenue guidance disappoints By Investing.com - Investing.com Nigeria
Illumina shares fall 5% as Q4 revenue guidance disappoints - Investing.com
Illumina, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 29, 2024 - Marketscreener.com
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024 - PR Newswire
Illumina (NASDAQ:ILMN) Hits New 12-Month HighStill a Buy? - MarketBeat
Illumina Inc (ILMN) Trading 3.49% Higher on Nov 4 - GuruFocus.com
Enabling single-cell sequencing for every laboratory - Illumina
Illumina stock soars to 52-week high, reaches $152.12 - Investing.com
Illumina to present updates on several key innovations in whole-genome sequencing at ASHG meeting - The Financial Express
Illumina Q3 24 Earnings Conference Call At 4:30 PM ET - Nasdaq
Epigenetics Market Types and Applications, Drivers, Ongoing - openPR
At ASHG, Illumina to Share Updates to Sequencing, Proteomics, and Single-Cell Technologies - Genetic Engineering & Biotechnology News
Argonautica Private Wealth Management Inc. Takes $569,000 Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by New York State Teachers Retirement System - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
NXP, Illumina, Vertex set to report earnings Monday By Investing.com - Investing.com Australia
NXP, Illumina, Vertex set to report earnings Monday - Investing.com
Stephens Investment Management Group LLC Has $28.01 Million Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting - PR Newswire
Illumina Leads the Way With Its Steps Against Cancer Campaign - ReportAlert.info
Hudson Valley Investment Advisors Inc. ADV Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
What Analyst Projections for Key Metrics Reveal About Illumina (ILMN) Q3 Earnings - MSN
Comprehensive Study of Microfluidic Market 2024-2031 Trends, - openPR
Celebrating Diwali in India for the first time in 20 years - Illumina
Illumina leads the way with its Steps Against Cancer campaign - Illumina
CSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Deltec Asset Management LLC - MarketBeat
(ILMN) Trading Report - Stock Traders Daily
Strategic Buy Lights Up This Biotech Stock: Time to Invest? - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):